Mycenax Biotech Inc. AI Stock Analysis
Mycenax Biotech Inc. (4726) AI Stock Analysis
Mycenax Biotech Inc.
(TPEx:4726)
The score is driven primarily by weak financial performance: Mycenax still sells below cost, posts a -60.6% net margin, has seen equity fall by roughly half in three years while debt rose, and has never generated positive free cash flow in the period reviewed. Technicals reinforce the caution, with the price below all major moving averages and negative MACD, though the very low RSI and Stochastic readings indicate the stock is heavily oversold. Valuation offers no support given negative earnings and no dividend. The main positive offsets are the clear improving trend — revenue growth, two consecutive years of narrowing losses, and a sharply reduced cash burn — but the turnaround remains unproven and dependent on further margin recovery or additional financing.
Mycenax Biotech Inc. (4726) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.64B
- Dividend Yield
- ―
- Average Volume (3M)
- 131.46K
- Price to Earnings (P/E)
- -12.2
- Beta (1Y)
- 0.40
- Revenue Growth
- 52.81%
- EPS Growth
- 38.53%
- Country
- TW
- Employees
- 387
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Mycenax Biotech Inc. Business Overview & Revenue Model
Company Description
Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States....
Mycenax Biotech Inc. Financial Statement Overview
Summary
Mycenax remains deeply unprofitable. Gross margin is still negative at -24.5% and the net loss of NT$449M equates to a -60.6% net margin, meaning the company cannot yet cover its production costs. Shareholders' equity has nearly halved over three years to NT$1.60B while debt rose to NT$1.07B, lifting leverage to 0.67x equity and keeping return on equity around -28%. Cash flow has never been positive in the period reviewed, with free cash flow at -NT$126M. The offsetting positives are a clear improving trend: revenue recovered to NT$740M, gross and net losses have narrowed for two consecutive years, capex has normalized, and the free cash burn has been cut by roughly three-quarters. The trajectory is encouraging but the profile stays high-risk and reliant on further margin recovery or external funding.
Income Statement
23NegativeBalance Sheet
41NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 815.87M | 740.24M | 683.92M | 652.62M | 732.28M | 774.27M |
| Gross Profit | -143.34M | -181.41M | -241.36M | -375.19M | -113.67M | 137.61M |
| EBITDA | -111.20M | -119.51M | -136.46M | -339.48M | -160.34M | 82.83M |
| Net Income | -381.91M | -448.63M | -467.13M | -682.85M | -453.63M | -89.86M |
Balance Sheet | ||||||
| Total Assets | 3.28B | 3.26B | 3.37B | 3.77B | 4.45B | 3.14B |
| Cash, Cash Equivalents and Short-Term Investments | 264.94M | 225.75M | 278.06M | 668.89M | 1.34B | 295.43M |
| Total Debt | 1.12B | 1.07B | 883.39M | 726.28M | 955.85M | 744.64M |
| Total Liabilities | 1.87B | 1.66B | 1.34B | 1.32B | 1.35B | 1.23B |
| Stockholders Equity | 1.41B | 1.60B | 2.02B | 2.45B | 3.11B | 1.91B |
Cash Flow | ||||||
| Free Cash Flow | -22.44M | -126.32M | -522.19M | -428.78M | -789.16M | -1.26B |
| Operating Cash Flow | 123.94M | -27.24M | -191.68M | -131.18M | -150.19M | -146.23M |
| Investing Cash Flow | -138.05M | -112.44M | -174.93M | -443.15M | -745.24M | -1.03B |
| Financing Cash Flow | 65.44M | 94.91M | 116.58M | -229.73M | 1.93B | 1.17B |
Mycenax Biotech Inc. Peers Comparison
Overall Rating
TW:176064Neutral
TW:317642Neutral- TW:472635Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1760 | 64Neutral | TWD 4.23B | 24.71 | ― | 4.19% | 1.43% | -5.24% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:3176 | 42Neutral | TWD 4.62B | -16.65 | ― | ― | 1.11% | -94.39% |
| TW:4726 | 35Underperform | TWD 4.76B | -12.16 | ― | ― | 52.81% | 38.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4726 | Mycenax Biotech Inc. | 22.40 | -11.25 | -33.43% | |
| TW:1760 | Panion & BF Biotech Inc. | 47.70 | -16.06 | -25.18% | |
| TW:3176 | Medigen Biotechnology Corporation | 30.10 | 0.20 | 0.67% | |
| TW:6610 | TWi Biotechnology, Inc | 17.50 | -19.34 | -52.50% | |
| TW:6634 | Sinew Pharma, Inc. | 63.20 | 22.70 | 56.05% | |
| TW:7920 | Tripartite Therapeutics, Inc. | 6.85 | -0.23 | -3.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026